US Pharma MarketingLilly enters GLP-2 space in $75M upfront deal with Korean biotech Hanmi
Eli Lilly, which has made billions off of the success of its GLP-1 drugs, is now making a play for GLP-2s through a licensing deal with Hanmi. The Indianapolis drugmaker will pay $75 million upfront in a global pact for a GLP-2 analog called sonefpeglutide. The Seoul-based biotech could receive up to $1.185 billion in R&D, regulatory and sales milestone payments, on top of potential royalties. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board…
Eli Lilly, which has made billions off of the success of its GLP-1 drugs, is now making a play for GLP-2s through a licensing deal with Hanmi.
The Indianapolis drugmaker will pay $75 million upfront ...
Source: Endpoints News